We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 124

Even in California, Failure To Report Requires Something Reportable
  • Reed Smith LLP
  • USA
  • October 11 2018

It would seem to go without saying that for a defendant to be liable for the purported “common-law” claim of failure to report adverse events to the


Heck No, FDCA Violations Can’t Be Inferred Merely From Product Malfunctions
  • Reed Smith LLP
  • USA
  • September 24 2018

We recently commented on Sumpter v. Allergan, Inc., 2018 WL 4335519 (E.D. Mo. Sept. 11, 2018), for several reasons - all bad - but one stands out, the


Taking Out the Laundry With TwIqbal
  • Reed Smith LLP
  • USA
  • August 22 2018

In medical device product liability cases to which preemption by reason of FDA pre-market approval (“PMA”) applies, courts have consistently


Breaking News - Supreme Court Grants Review in Fosamax Preemption Case
  • Reed Smith LLP
  • USA
  • June 28 2018

Today, on the last day of the United States Supreme Court’s 2018 Term, the Court issued an order granting review (“certiorari”) in Merck Sharp & Dohme


Potentially, the Mother of All Off-Label Uses, as FDA Backs Down
  • Reed Smith LLP
  • USA
  • June 14 2018

Researchers at Temple University here in Philly recently published a scientific article, “Learning Impairments, Memory Deficits, and Neuropathology in


Breaking News - Solicitor General Recommends Grant and Reversal in Fosamax Appeal
  • Reed Smith LLP
  • USA
  • May 23 2018

We immediately called for the further appeal and reversal of the hideous decision in In re Fosamax (Alendronate Sodium) Products Liability Litigation


Federal Right To Try Legislation - Is It Any Better? - 2018 Edition
  • Reed Smith LLP
  • USA
  • March 23 2018

A little more than six months ago, we reviewed then-pending federal right-to-try legislation. Since then it’s become a shiny object, capable of


More Legislation To Watch
  • Reed Smith LLP
  • USA
  • January 29 2018

Like a lot of large firms, Reed Smith has a number of blogs. We don't mention them much because, DDL has product liability pretty well covered, and


The Highs Celebrating the Ten Best Prescription DrugMedical Device Decisions of 2017
  • Reed Smith LLP
  • USA
  • December 28 2017

Ending the year on a high note is one thing that the blog tries to do - with the top ten drugdevice product liability decisions of the year


Inauspicious Debut for Depakote Plaintiffs’ First Amendment Argument
  • Reed Smith LLP
  • USA
  • December 27 2017

We've been aware of the other side attempting to construct a First Amendment counter-argument to our preemption defense for some time. It first